FRONTEO Healthcare, Inc. (“FRONTEO Healthcare”), a subsidiary of FRONTEO, Inc. (“FRONTEO”) today announces the termination of the joint research agreement with the Japanese Foundation for Cancer Research, begun in January 2017, aimed at developing a Cancer Precision Medicine System. While certain results were realized, the parties have jointly agreed to not pursue the next stage of research.
 
FRONTEO Healthcare will continue to study and develop “Precision Medicine,” a method of selecting the best treatment methodologies and medicines for individual patients by leveraging the latest medical research, medical and nursing records, and genetic information together with FRONTEO’s Artificial Intelligence technology.  
 
FRONTEO does not anticipate this termination having a material impact on fiscal year 2018 results.